Price (delayed)
$1.69
Market cap
$32.93M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.11
Enterprise value
$10.7M
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS).
There are no recent dividends present for ANVS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.